Back to today’s briefing

Story perspectives

FDA Seeks Comment on Removing GLP-1s, Deadline June 29

5/1/2026

50 11 Full Breakdown

Summary

Story summary

The FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk-drug list.
The agency opened a comment period that ends on June 29.
Novo Nordisk and Eli Lilly said the exclusion confirms there is no clinical need for compounding their GLP-1 drugs.
Analysts note that most telehealth firms use 503A pharmacies, indicating the change may not affect existing GLP-1 compounding operations.

1 of 1

Story summary

The FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk-drug list.
The agency opened a comment period that ends on June 29.
Novo Nordisk and Eli Lilly said the exclusion confirms there is no clinical need for compounding their GLP-1 drugs.
Analysts note that most telehealth firms use 503A pharmacies, indicating the change may not affect existing GLP-1 compounding operations.